title: No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL.
authors.affiliation: Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
authors.forename: Thomas R
authors.initials: TR
authors.lastname: O'Brien
authors.affiliation: Toronto Centre for Liver Disease, University of Toronto, Toronto, Canada.
authors.forename: Jordan J
authors.initials: JJ
authors.lastname: Feld
authors.affiliation: Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD.
authors.forename: Shyam
authors.initials: S
authors.lastname: Kottilil
authors.affiliation: Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
authors.forename: Ruth M
authors.initials: RM
authors.lastname: Pfeiffer
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage*; D005449:Fluorenes / Q000008:administration & dosage*; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D012367:RNA, Viral / Q000097:blood; D000069474:Sofosbuvir / Q000008:administration & dosage*; D013997:Time Factors
chemical_list: D000998:Antiviral Agents; D001562:Benzimidazoles; D005449:Fluorenes; D012367:RNA, Viral; C586541:ledipasvir; D000069474:Sofosbuvir